Cell line-derived xenograft (CDX) models are a well established and widely used in vivo option for preclinical drug efficacy testing. Human tumor samples are cultured as cell lines, then inoculated into immunodeficient mice to test anti-tumor compounds. Benefits of CDX models are its cost effectiveness, fast turnaround time and high efficiency of xenotransplantation.
LIDE has a growing bank of over 50 cell line-derived xenograft (CDX) mouse models.
| Cancer | Cell line | Cancer | Cell line |
| Bladder | T24, SW780 | Glioblastoma | U87-MG, U251 |
| Colon | RKO, HCT-116, LOVO, SW620, COLO 205, HT-29, GP2D, SW480 | Esophageal | KYSE30 |
| Breast | MDA-MB-468, HCC-1954, MDA-MB-231, HCC1806, ZR-75-1, JIMT-1 | Cervical | HeLa, C-33A |
| Gastric | KATO III, NCI-N87, BGC823, MKN45, N87-Claudin 18.2 | Myeloma | MOLP-8 |
| Pancreatic | MIA PaCa-2, PANC-1, ASPC-1, BXPC-3 | Osteoblastoma | K7M2 |
| Prostate | PC-3, LNCap, Du 145, 22Rv1 | Lung | NCI-H226, A549,Clau-3, NCI-H1975, SHP-77, NCI-H460, NCI-H2009, NCI-H2122, HCC827, NCI-H292 |
| Kidney | A498, 786-O Embryonic: HEK293-Claudin 18.2 |
Liver | HepG2, Hep-3B, Huh7, SNU-398 |
| Melanoma | A375 | Ovarian | SK-OV-3, OVCAR-3, A2780, PA-1 |
| Epidermoid carcinoma | A431 | Retinoblastoma | WERI-Rb-1，Y-79 |
| Leukemia/Lymphoma | Raji, NALM6, MV-4-11, K-562, MOLT-4, OCI-LY3,Daudi, Ramos(RA 1) | Human oral squamous | SCC090 |
| Fibrosarcoma/Rhabdo myosarcoma | HT-1080 | Total | 70 |
CDX models can also be used in our humanized mouse models for evaluating immunotherapies.
LIDE has a biobank with more than 100 human cancer cell lines, and we receive fresh patient samples everyday due to our RWE study in partnership with hospitals all over China. Many cell lines are drug resistant or contain popular target expression phenotypes.
| Cancer | Cell line | Cancer | Cell line |
| Colon | Lovo,HT-29,Colo205,SW48,SW480,SW837,HCT-116,SW620,GP2D,RKO,SK-CO-1,DLD1,Colo 741 | Ovarian | SK-OV-3, OVCAR-3, A2780, PA-1, ES-2, EFO-21, TOV-21G |
| Breast | MDA-MB-231, MDA-MB-468, HCC-1954,BT474,MDA-MB-157,MDA-MB-453,SK-BR-3, T-47D, MCF7 | Pancreatic | MIA-Paca-2, Aspc-1, BXPC-3, HPAC, PANC-05.04, PANC-1, SW1990, Panc10.05, Capan 2 |
| Gastric | MKN-45, NCI-N87, SNU-16, KATO III, KATO3-T5-BN,BGC823,SNU-5,NUGC4,MKN28, Hep3B, Hs746T | Lung | A549, CALU-1, H460, DM14, H2009, H1975, H1703, HCC827, H2122, NCI-H226, Calu-3, H1299, H23, H358, SK-LU-1, EBC-1, H1993, H596, NCI-H441 |
| Prostate | PC-3 LNCap, Du 145, 22RV1 | Osteosarcoma | 143B, MG-63, Saos-2, U-2 OS |
| Melanoma | A375, MOLP-8, SK-MEL-5 | Esophageal | KYSE30, OE19 |
| Liver | HepG2, Hep-3B, Huh7, SNU-398, SK-HEP-1 | Glioblastoma | U87MG, U251, A172, LN-229, U-118 MG |
| Lymphoma | Raji, Daudi, NALM-6, KARPAS-299, MV4-11, OCI-LY3 | AML | U87MG, U251, A172, LN-229, U-118 MG |
| Leukemia/MM | K562, Jurkat | Bladder Cancer | 5637 |
| Fibrosarcoma | HT-1080 | Kidney | A498 |
| Epidermoid carcinoma | A431 | Cervical | Hela |
| Total | 106 |